#EVOK

Evoke Pharma and QOL Medical Announce Expiration of Tender Offer Evoke Stockholders Received $11.00 Per Share in Cash. SOLANA BEACH, Calif., and VERO BEACH, Fla., Dec. 17, 2025/ PRNewswire/-- Evoke Pharma, Inc. and QOL Medical, LLC today announced that the tender offer by QOL-EOS Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of QOL Medical, to acquire all of the outstanding shares of common stock, par value...

2 months ago

#EVOK Evoke Pharma and QOL Medical Announce Expiration of Tender Offer

www.stocktitan.net/news/EVOK/evoke-pharma-a...

0 0 0 0

4 months ago

#EVOK Evoke Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/EVOK/evoke-pharma-r...

0 0 0 0

4 months ago

JUST IN: ( NASDAQ: #EVOK ) Evoke Pharma Inc. (NASDAQ: EVOK) Records 52-Week High Tuesday Morning

0 0 0 0

Evoke Pharma Enters into Definitive Agreement to Be Acquired by QOL Medical Evoke Pharma (NASDAQ: EVOK) agreed to be acquired by QOL Medical for $11.00 per share in cash, a 139.7% premium to Evoke's November 3, 2025 closing price. The boards of both companies approved the transaction, which will be effected via a tender offer and is expected to close in the fourth quarter of 2025. QOL Medical said it will finance the deal with cash on hand and the transaction is not subject to a financing condition.The announcement highlights Evoke’s commercial product GIMOTI (metoclopramide) nasal spray, described as the first and only FDA-approved nasal spray for acute and recurrent diabetic gastroparesis in adults. Upon successful tender, a QOL subsidiary will merge into Evoke and any remaining shares will be cancelled and converted into the same cash price per share.

4 months ago

#EVOK Evoke Pharma Enters into Definitive Agreement to Be Acquired by QOL Medical

www.stocktitan.net/news/EVOK/evoke-pharma-e...

0 0 0 0

@conkers3.bsky.social

4 months ago

#EVOK 41.6p✅

✅William Hill owner #Evoke has revealed a 5% increase in revenue to £435 million in Q3, boosted by a return to growth in its betting shop estate.

RNS 📸via jzrdan on X

0 0 0 0

Evoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell Relationship Evoke Pharma (NASDAQ: EVOK) has announced significant expansion of access to its GIMOTI® nasal spray through new strategic partnerships. The company has secured relationships with Omnicell (NASDAQ: OMCL) and Brentwood Pharmacy, which will substantially increase GIMOTI's availability through specialty pharmacy networks.The Omnicell partnership will facilitate GIMOTI distribution to major gastroenterology organizations, including Gastro Health (150 locations across 7 states) and OneGI (200+ gastroenterologists across multiple states). These partnerships are expected to nearly double the number of specialty pharmacies with access to GIMOTI, the only FDA-approved nasal spray for adults with acute and recurrent diabetic gastroparesis.

6 months ago

#EVOK Evoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell Relationship

www.stocktitan.net/news/EVOK/evoke-pharma-a...

0 0 0 0

Stock Master

@stockmaster70.bsky.social

6 months ago

📢 Stocks Trending NOW: #WMT #THAR #NEGG #AEMD #BA #APM #CRWV #EVOK #GRO #NIO

1 0 0 0

18-Year Patent Protection: Evoke Pharma's Gastroparesis Nasal Spray GIMOTI Gains FDA Orange Book Listing Evoke Pharma's U.S. Patent No. 12,377,064 for GIMOTI nasal spray extends protection to 2038, 8 years beyond previous patent. Covers moderate to severe gastroparesis treatment.

6 months ago

#EVOK Evoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange Book

www.stocktitan.net/news/EVOK/evoke-pharma-a...

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

7 months ago

Evoke Pharma Posts 47 Percent Q2 Growth | The Motley Fool

#EVOK #ad72b096-025b-4d42-a457-9a42d10200fe #data-news

Origin | Interest | Match

0 0 0 0

Gastroparesis Drug Maker Evoke Posts Strong Growth as GIMOTI Adoption Accelerates Specialty pharma reports $3.8M Q2 revenue, 20% prescriber growth, and projects $16M full-year sales for gastroparesis nasal spray GIMOTI. Get detailed financials.

7 months ago

#EVOK Evoke Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/EVOK/evoke-pharma-r...

0 0 0 0

GIMOTI Gastroparesis Treatment Secures 2-Year Patent Extension, Strengthening Market Position Through 2038 New USPTO patent extends GIMOTI nasal spray's market exclusivity for gastroparesis treatment. Discover how this 2-year extension impacts Evoke Pharma's future. Learn more.

7 months ago

#EVOK Evoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Extended Exclusivity to Late 2038

www.stocktitan.net/news/EVOK/evoke-pharma-a...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

8 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Wed Jul 9th - #RIG #RXRX #IREN #CIFR #BTBT #SRFM #EVOK #VLRS #MBIO #SOBR #TOI #SBET #PROK #MLGO #LEU #HUT #GAME #VOR #CLDI #HIVE - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

8 months ago

JUST IN: ( NASDAQ: #EVOK ) Stocks to Watch: Innovation, Expansion, and Breakout Biotech Catalysts

0 0 0 0

8 months ago

Breaking News: ( NASDAQ: #EVOK ) Evoke Pharma Receives Notice from USPTO for GIMOTI Extending Orange Book Listings to 2036

0 0 0 0

Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036 Evoke Pharma (NASDAQ: EVOK) has received a Notice of Allowance from the USPTO for a patent application covering GIMOTI® (metoclopramide nasal spray) use in moderate to severe gastroparesis patients. The new patent, upon issuance, will extend market exclusivity until December 2036 and will be listed in the FDA's Orange Book.GIMOTI® is the only FDA-approved, non-oral, self-administered metoclopramide formulation for treating symptoms of acute and recurrent diabetic gastroparesis in adults. The treatment is particularly valuable as gastroparesis can impair the absorption of oral medications. The company has filed an additional U.S. continuation application for further claims related to this patient population.

8 months ago

#EVOK Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036

www.stocktitan.net/news/EVOK/evoke-pharma-r...

0 0 0 0

Evoke Pharma Crushes Q1 Expectations: 77% Revenue Jump and 73% Fill Rate Growth Signal GIMOTI Breakthrough Q1 sales hit $3.1M amid 73% fill rate surge. Discover how GIMOTI's expanding prescriber network and GLP-1 strategy are transforming patient care. See full results.

10 months ago

#EVOK Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/EVOK/evoke-pharma-r...

0 0 0 0

Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Evoke Pharma (NASDAQ: EVOK) reported strong financial results for Q4 and full-year 2024. Q4 revenue increased 24.6% to $3.3 million compared to Q3 2024, while full-year revenue grew 97.8% to $10.2 million year-over-year.Key achievements include: 46% growth in prescriber base to 2,553 total prescribers72% increase in fill rates year-over-year22% rise in patient enrollments$14.3 million raised through equity financingsCash runway extended into Q1 2026The company's GIMOTI treatment for diabetic gastroparesis gained further validation through award-winning research presented at ACG 2024, particularly highlighting benefits for GLP-1 users. Evoke projects 2025 net revenue of approximately $16 million, representing a 60% increase from 2024.

1 year ago

#EVOK Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/EVOK/evoke-pharma-i...

0 0 0 0

@conkers3.bsky.social

1 year ago

William Hill owner Evoke expects earnings to beat market forecasts Expect shares in William Hill owner Evoke PLC to get off to a strong start when the market opens. That's because the bookmaker said full-year earnings for...

#EVOK 🆙+8%✅74.5p✅
After a positive trading update:
✅Revenues +12% to 13% yoy
✅Online growth was even stronger, climbing 16% to 17%

via Proactive_UK
#$EVOK.L William Hill owner #Evoke expects earnings to beat market forecasts www.proactiveinvestors.co.uk/companies/ne...

0 0 0 0

marketshareai.uk

@marketshareai.bsky.social

1 year ago

🚙 Evoke Reports Strong Q4 Growth, Exceeds FY24 EBITDA Expectations. Betting giant exceeds expectations, signaling continued success in consumer cyclical industry.

Get ahead with today's top stories 👇

https://marketshareai.uk/news/lse/evok/6781T

#EVOK #AIM #FTSE

0 0 0 0

marketshareai.uk

@marketshareai.bsky.social

1 year ago

🚗Evoke delivered strong Q4 growth & topped FY24 EBITDA targets. Betting giant closes year exceeding all expectations, signaling continued momentum in the new year. #EVOK

Get ahead with today's top stories 👇

https://marketshareai.uk/news/lse/evok/6781T

#EVOK #AIM #FTSE

0 0 0 0

marketshareai.uk

@marketshareai.bsky.social

1 year ago

🎰 Evoke smashes Q4 forecasts, strong close to FY24 sees bookmaker exceed already bullish bottom line targets. Looks like smooth sailing ahead. #EVOK

Get ahead with today's top stories 👇

https://marketshareai.uk/news/lse/evok/6781T

#EVOK #AIM #FTSE

0 0 0 0

1 year ago

Just In: ( NASDAQ: #EVOK ) Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends

#StockMarket #News

0 0 0 0

Evoke Pharma's GIMOTI Set to Become Primary Treatment as Domperidone Supply Ends; Real-World Data Shows 68% Drop in Hospitalizations As domperidone supply ends in 2025, GIMOTI emerges as key FDA-approved treatment for diabetic gastroparesis, showing remarkable 60% reduction in ER visits versus alternatives.

1 year ago

#EVOK Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends

www.stocktitan.net/news/EVOK/evoke-pharma-h...

0 0 0 0

Evoke Pharma Secures Key Patents for GIMOTI Gastroparesis Nasal Spray Through 2029 | EVOK Stock News Evoke Pharma strengthens IP protection for GIMOTI, its FDA-approved nasal spray treatment for diabetic gastroparesis, with two new patent allowances extending through 2029.

1 year ago

#EVOK Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI®

#StockMarket #stocks #news

www.stocktitan.net/news/EVOK/evoke-pharma-r...

0 0 0 0

1 year ago

BREAKING NEWS: ( NASDAQ: #EVOK ) Evoke Pharma stock surges over 100%-here's why

#StockMarket #News

1 0 0 0

1 year ago

News; ( NASDAQ: #EVOK ) Evoke Pharma and EVERSANA Present Positive GIMOTI Data at ACG

#StockMarket #News

1 0 0 0